Enovis Corp (ENOV) - Total Assets
Based on the latest financial reports, Enovis Corp (ENOV) holds total assets worth $3.83 Billion USD as of December 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. See ENOV net asset value for net asset value and shareholders' equity analysis.
Enovis Corp - Total Assets Trend (2004–2025)
This chart illustrates how Enovis Corp's total assets have evolved over time, based on quarterly financial data.
Enovis Corp - Asset Composition Analysis
Current Asset Composition (December 2025)
Enovis Corp's total assets of $3.83 Billion consist of 31.5% current assets and 68.5% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 1.0% |
| Accounts Receivable | $442.79 Million | 11.6% |
| Inventory | $584.38 Million | 15.2% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $1.24 Billion | 32.3% |
| Goodwill | $718.30 Million | 18.7% |
Asset Composition Trend (2004–2025)
This chart illustrates how Enovis Corp's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see ENOV market cap.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Enovis Corp's current assets represent 31.5% of total assets in 2025, an increase from 0.0% in 2004.
- Cash Position: Cash and equivalents constituted 1.0% of total assets in 2025, up from 0.0% in 2004.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 50.0% of total assets, an increase from 0.0% in 2004.
- Asset Diversification: The largest asset category is intangible assets at 32.3% of total assets.
Enovis Corp Competitors by Total Assets
Key competitors of Enovis Corp based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Shenzhen New Industries Biomedical
SHE:300832
|
China | CN¥9.58 Billion |
|
Jafron Biomedical Co Ltd
SHE:300529
|
China | CN¥5.54 Billion |
|
Zhejiang Orient Gene Biotech Co Ltd
SHG:688298
|
China | CN¥7.51 Billion |
|
Shanghai ZJ Bio-Tech Co. Ltd. A
SHG:688317
|
China | CN¥3.72 Billion |
|
Guangdong Transtek Medical Electronics Co Ltd
SHE:300562
|
China | CN¥1.42 Billion |
|
Emvision Medical Devices Ltd
AU:EMV
|
Australia | AU$15.57 Million |
|
DRGEM Corporation
KQ:263690
|
Korea | ₩119.28 Billion |
|
Diagnostic Medical Systems SA
PA:ALDMS
|
France | €57.17 Million |
Enovis Corp - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 2.02 | 2.17 | 1.33 |
| Quick Ratio | 1.04 | 1.13 | 0.94 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $608.59 Million | $617.45 Million | $519.55 Million |
Enovis Corp - Advanced Valuation Insights
This section examines the relationship between Enovis Corp's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 0.87 |
| Latest Market Cap to Assets Ratio | 0.35 |
| Asset Growth Rate (YoY) | -18.7% |
| Total Assets | $3.83 Billion |
| Market Capitalization | $1.34 Billion USD |
Valuation Analysis
Below Book Valuation: The market values Enovis Corp's assets below their book value (0.35x), which may indicate investor concerns about asset quality or future growth.
Significant Asset Reduction: Enovis Corp's assets decreased by 18.7% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Enovis Corp (2004–2025)
The table below shows the annual total assets of Enovis Corp from 2004 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | $3.83 Billion | -18.73% |
| 2024-12-31 | $4.72 Billion | +4.64% |
| 2023-12-31 | $4.51 Billion | +5.52% |
| 2022-12-31 | $4.27 Billion | -49.82% |
| 2021-12-31 | $8.52 Billion | +15.84% |
| 2020-12-31 | $7.35 Billion | -0.48% |
| 2019-12-31 | $7.39 Billion | +11.86% |
| 2018-12-31 | $6.60 Billion | -1.75% |
| 2017-12-31 | $6.72 Billion | +5.26% |
| 2016-12-31 | $6.39 Billion | -5.16% |
| 2015-12-31 | $6.73 Billion | -7.07% |
| 2014-12-31 | $7.25 Billion | +10.06% |
| 2013-12-31 | $6.58 Billion | +7.39% |
| 2012-12-31 | $6.13 Billion | +463.11% |
| 2011-12-31 | $1.09 Billion | +6.50% |
| 2010-12-31 | $1.02 Billion | +1.89% |
| 2009-12-31 | $1.00 Billion | +9.86% |
| 2008-12-31 | $913.08 Million | +1.84% |
| 2007-12-31 | $896.54 Million | +12.46% |
| 2006-12-31 | $797.23 Million | +13.80% |
| 2005-12-31 | $700.57 Million | -1.03% |
| 2004-12-31 | $707.88 Million | -- |
About Enovis Corp
Enovis Corporation, a medical technology company, focuses on developing clinically differentiated solutions in the United States and internationally. It operates through two segments: Prevention and Recovery, and Reconstructive segments. The Prevention and Recovery segment offers rigid and soft orthopedic bracing, hot and cold therapy, bone growth stimulators, vascular therapy systems and compres… Read more